Literature DB >> 23202701

Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells.

Tanya I Stoyanova1, Andrew S Goldstein.   

Abstract

Entities:  

Year:  2012        PMID： 23202701      PMCID： PMC3739119          DOI： 10.1038/aja.2012.133

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  12 in total

Review 1.  Overcoming castration resistance in prostate cancer.

Authors:  Che-Kai Tsao; Alexander C Small; Matthew D Galsky; William K Oh
Journal:  Curr Opin Urol       Date:  2012-05       Impact factor: 2.309

Review 2.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

3.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Authors:  Josep Domingo-Domenech; Samuel J Vidal; Veronica Rodriguez-Bravo; Mireia Castillo-Martin; S Aidan Quinn; Ruth Rodriguez-Barrueco; Dennis M Bonal; Elizabeth Charytonowicz; Nataliya Gladoun; Janis de la Iglesia-Vicente; Daniel P Petrylak; Mitchell C Benson; Jose M Silva; Carlos Cordon-Cardo
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

4.  siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.

Authors:  Qi-Fa Ye; Yi-Chuan Zhang; Xiao-Qing Peng; Zhi Long; Ying-Zi Ming; Le-Ye He
Journal:  Asian Pac J Cancer Prev       Date:  2012

5.  Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.

Authors:  Ilya V Ulasov; Suvobroto Nandi; Mahua Dey; Adam M Sonabend; Maciej S Lesniak
Journal:  Mol Med       Date:  2010-10-15       Impact factor: 6.354

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Authors:  Jichao Qin; Xin Liu; Brian Laffin; Xin Chen; Grace Choy; Collene R Jeter; Tammy Calhoun-Davis; Hangwen Li; Ganesh S Palapattu; Shen Pang; Kevin Lin; Jiaoti Huang; Ivan Ivanov; Wei Li; Mahipal V Suraneni; Dean G Tang
Journal:  Cell Stem Cell       Date:  2012-05-04       Impact factor: 24.633

9.  Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling.

Authors:  Vinagolu K Rajasekhar; Lorenz Studer; William Gerald; Nicholas D Socci; Howard I Scher
Journal:  Nat Commun       Date:  2011-01-18       Impact factor: 14.919

10.  Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Authors:  Teresa Maria Santos Amaral; Daniela Macedo; Isabel Fernandes; Luis Costa
Journal:  Prostate Cancer       Date:  2012-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.